Did the FDA actually lift its ban on peptides in 2024?

What did @juulianbecerra actually say?

On April 15th, @juulianbecerra claimed the FDA was set to remove 12 peptides from its Category 2 Do Not Compound (DNCL) list within seven days, crediting RFK Jr.'s public pressure as the catalyst. He also argued that the unregulated "research use only" peptide market is genuinely dangerous because nobody is testing for purity or endotoxins.

To summarize his core claims: RFK Jr. announced on Joe Rogan that the FDA had "illegally" placed peptides on the Do Not Compound list, the current research-chemical supply chain has no meaningful quality controls, and this regulatory reversal would allow patients to access compounded peptides under physician supervision with verified purity. He was careful to frame this as a good thing for consumer safety, not just a win for peptide enthusiasts.

Does the science back this up?

On the contamination risk in unregulated peptide markets, the science is solidly on his side. The claim that research-use-only peptides carry serious purity and endotoxin risks is well-documented and not remotely controversial among researchers who study this.

A 2021 analysis published in JAMA Internal Medicine (Cohen et al.) examined peptides and other compounds sold through online research chemical vendors and found that labeling accuracy was inconsistent and contamination screening was absent in most cases. Endotoxins, which are bacterial lipopolysaccharides that can trigger serious immune reactions, are a genuine concern in any injectable compound not produced under pharmaceutical-grade sterile conditions. The FDA's own compounding guidelines under USP 797 exist precisely because injectable preparations have a different risk profile than oral drugs. The creator's point that "no one's checking" the purity or endotoxin levels in research-use peptides is not alarmist, it is the baseline reality of an unregulated supply chain.

What did they get wrong (or right)?

The creator got the contamination argument right. The framing around RFK Jr. and the word "illegal" is where things get complicated and deserve scrutiny.

RFK Jr.'s characterization that the FDA "illegally" moved peptides to the DNCL is a political assertion, not a settled legal finding. The FDA placed peptides like BPC-157 and TB-500 on the Category 2 DNCL under its authority interpreting the Federal Food, Drug, and Cosmetic Act, specifically the provisions added by the Drug Quality and Security Act of 2013. Whether that authority was applied correctly is a legitimate legal debate, but calling it flatly "illegal" overstates a contested interpretation. The creator repeated this framing without pushback.

He also stated that prices "will level out as competition enters the marketplace." That is speculative. Pharmaceutical-grade compounding adds real cost: sterility testing, endotoxin testing, potency verification. These are not trivial expenses. It is equally plausible that prices remain higher than the gray-market alternative, especially for patients without insurance coverage for compounded peptides.

On the positive side, his acknowledgment that "this is one of the few times I actually agree with regulatory oversight" is refreshingly honest for a peptide content creator. He did not tell viewers to go self-inject unverified compounds. Credit where it is due.

What should you actually know?

If this regulatory change holds, it matters, but it does not mean peptides are suddenly approved drugs with established safety profiles in humans.

Removing peptides from the DNCL means licensed compounding pharmacies can legally prepare them for patients with a valid prescription. It does not mean the FDA has reviewed clinical trial data and determined these peptides are safe and effective for the uses being marketed online. BPC-157, for example, has a substantial body of animal research but very limited controlled human trial data as of 2024. TB-500 is in a similar position. Patients and clinicians should understand that "compounded" and "FDA-approved" are not the same category.

What changes practically: a compounding pharmacy operating under USP 797 standards will test for sterility and endotoxins and verify potency before dispensing. That is a real and meaningful improvement over buying from a research chemical vendor. What does not change: the underlying evidence base for many of these peptides in humans remains thin. Physician supervision, which the creator correctly emphasizes, is not a formality here. It is genuinely important context for determining whether any of this is appropriate for a specific patient.

The bottom line

@juulianbecerra's core consumer-safety argument is legitimate and grounded in real regulatory and contamination concerns. His political framing around "illegal" bans is less solid and worth treating skeptically. The regulatory development he describes, if confirmed and implemented, represents a meaningful shift in how compounded peptides can be accessed. It is not a green light to assume these compounds are proven therapies. It is a shift from a completely unregulated gray market to a regulated compounding framework, which is a lower bar than most people in this conversation seem to acknowledge.